-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TL-895 in Myelofibrosis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. TL-895 in Myelofibrosis Drug Details: TL-895 is under development for the treatment of myelofibrosis, chronic idiopathic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TL-895 in Chronic Lymphocytic Leukemia (CLL)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. TL-895 in Chronic Lymphocytic Leukemia (CLL) Drug Details: TL-895 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TL-895 in Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. TL-895 in Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis) Drug Details: TL-895 is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TL-925 in Keratoconjunctivitis Sicca (Dry Eye)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.TL-925 in Keratoconjunctivitis Sicca (Dry Eye)Drug Details:TL-925 is under development for the treatment of keratoconjunctivitis sicca...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TL-895 in Refractory Acute Myeloid Leukemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. TL-895 in Refractory Acute Myeloid Leukemia Drug Details: TL-895 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TL-895 in Relapsed Acute Myeloid Leukemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. TL-895 in Relapsed Acute Myeloid Leukemia Drug Details: TL-895 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TL-895 in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. TL-895 in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) Drug Details: TL-895 is under development for the...
-
Product Insights
TLS Grp – Opal Residence – Selangor
Equip yourself with the essential tools needed to make informed and profitable decisions with our TLS Grp - Opal Residence - Selangor report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into the TLS...
-
Product Insights
TL Cement – Baucau Cement Production Plant – Baucau
Equip yourself with the essential tools needed to make informed and profitable decisions with our TL Cement - Baucau Cement Production Plant - Baucau report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into...
-
Product Insights
Atira/ TL Housing – 450 Alexander Street Social Housing Tower – British Columbia
Equip yourself with the essential tools needed to make informed and profitable decisions with our Atira/ TL Housing - 450 Alexander Street Social Housing Tower - British Columbia report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BGB-24714 in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BGB-24714 in Solid Tumor Drug Details: BGB-24714 is under development for the treatment of advanced...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MCM-998 in Multiple Myeloma (Kahler Disease)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.MCM-998 in Multiple Myeloma (Kahler Disease)Drug Details:MCM-998 is under development for the treatment of multiple myeloma....
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BCMA-CAR-T in Multiple Myeloma (Kahler Disease)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.BCMA-CAR-T in Multiple Myeloma (Kahler Disease) Drug Details:Gene-modified cell therapy is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – LK-101 in Hepatocellular Carcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. LK-101 in Hepatocellular Carcinoma Drug Details: Cell therapy is under investigation for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – DX-126262 in Ureter Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.DX-126262 in Ureter CancerDrug Details:DX-126262 is under development for the treatment of HER2-positive or HER2-mutated unresectable...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NRC-2694 in Oral Cavity (Mouth) Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.NRC-2694 in Oral Cavity (Mouth) CancerDrug Details:NRC-2694 is under development for the treatment of recurrent head...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Fenebrutinib in Mantle Cell Lymphoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Fenebrutinib in Mantle Cell Lymphoma Drug Details:Fenebrutinib (GDC-0853, RG-7845) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AOND-21 in Lung Adenocarcinoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.AOND-21 in Lung AdenocarcinomaDrug Details:AOND-21 (formerly NOX-D21) is under development for the treatment of lung adenocarcinoma....
-
Product Insights
Neuromodulation Devices – Medtronic Plc – RESUME TL
GlobalData, the industry analysis specialist, has released its latest report: Neuromodulation Devices - Medtronic Plc - RESUME TL. The selling price or list price of a medical device is driven by numerous factors, such as therapy area and complexity of procedure, level of reimbursement, development costs, the number of competing manufacturers, product life cycle, and whether there have been any recent new technology or product launches. In addition, the final selling pricing of medical devices is also impacted by the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NBTXR-3 in Cervical Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. NBTXR-3 in Cervical Cancer Drug Details: NBTXR-3 is under development for the treatment of head and...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.